FDA Grants Accelerated Approval to Umbralisib for Marginal Zone and Follicular Lymphomas
During treatment with umbralisib, prophylaxis is recommended for Pneumocystis jirovecii pneumonia and to consider prophylactic antivirals to prevent CMV infection, including CMV reactivation